AiPD: Autoinhibited Protein Database

Q13242

Gene name	SRSF9 (SFRS9, SRP30C)
Protein name	Serine/arginine-rich splicing factor 9
Names	KP43, Killer cell lectin-like receptor subfamily D member 1, NK cell receptor, Pre-mRNA-splicing factor SRp30C, Splicing factor, arginine/serine-rich 9
Species	Homo sapiens (Human)
KEGG Pathway	hsa:8683
EC number
Protein Class

Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

155-221 (Predicted disordered autoinhibitory region) PR

Target domain
Relief mechanism
Assay	cis-regPred

AID

155-221 (Predicted disordered autoinhibitory region)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

References

Yeon JH et al. (2016) "Systems-wide Identification of cis-Regulatory Elements in Proteins", Cell Systems, 2, 89-100

Autoinhibited structure

Activated structure

1 structures for Q13242

Entry ID	Method	Resolution	Chain	Position	Source
AF-Q13242-F1	Predicted				AlphaFoldDB

119 variants for Q13242

Variant ID(s)	Position	Change	Description	Diseaes Association	Provenance
rs1186390648 CA386584253	2	S>W		No	ClinGen gnomAD
rs779113084 CA6828572	3	G>S		No	ClinGen ExAC TOPMed gnomAD
rs757706169 CA6828571	5	A>T		No	ClinGen ExAC TOPMed gnomAD
CA6828570 rs375455136	5	A>V		No	ClinGen ESP ExAC TOPMed gnomAD
rs1319557272 CA386584211	6	D>A		No	ClinGen TOPMed
rs936740323 CA244480304	6	D>E		No	ClinGen TOPMed gnomAD
rs926657643 CA244480296	7	E>V		No	ClinGen TOPMed gnomAD
rs761268364 CA6828568	8	R>P		No	ClinGen ExAC gnomAD
rs1565918414 CA386584181	9	G>D		No	ClinGen Ensembl
CA386584161 rs1592994299	11	E>K		No	ClinGen Ensembl
CA6828565 rs762674115	12	G>A		No	ClinGen ExAC gnomAD
CA6828566 rs528772255	12	G>S		No	ClinGen 1000Genomes ExAC gnomAD
CA6828560 rs768537684	19	G>V		No	ClinGen ExAC gnomAD
TCGA novel	20	N>S	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1167746878 CA386584032	22	P>L		No	ClinGen gnomAD
rs374780024 CA6828558	25	V>M		No	ClinGen ESP ExAC TOPMed gnomAD
CA6828557 rs772176841	26	R>C		No	ClinGen ExAC gnomAD
rs1197713806 CA386583990	27	E>K		No	ClinGen gnomAD
rs1197713806 CA386583988	27	E>Q		No	ClinGen gnomAD
CA386583969 rs1250789428	28	K>R		No	ClinGen gnomAD
CA386583971 rs1250789428	28	K>T		No	ClinGen gnomAD
CA386583943 rs1336838568	30	L>F		No	ClinGen gnomAD
rs1293906218 CA386583934	31	E>G		No	ClinGen gnomAD
rs1367454528 CA386583939	31	E>Q		No	ClinGen gnomAD
CA6828551 rs200055366	32	D>E		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
CA6828553 rs754164143	32	D>N		No	ClinGen ExAC gnomAD
TCGA novel	35	Y>*	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs145350287 CA6828548	35	Y>F		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
rs1397316277 CA386583868	37	Y>H		No	ClinGen gnomAD
rs764890661 CA386583845	39	R>H		No	ClinGen ExAC gnomAD
CA6828546 rs764890661	39	R>P		No	ClinGen ExAC gnomAD
rs1592994218 CA386583840	40	I>V		No	ClinGen Ensembl
rs1017747664 CA244480206	41	R>C		No	ClinGen TOPMed
CA6828545 rs761380426	42	E>Q		No	ClinGen ExAC gnomAD
rs1184462290 CA386583808	43	I>V		No	ClinGen gnomAD
CA6828539 rs745901220	48	R>P		No	ClinGen ExAC gnomAD
rs745901220 CA386583743	48	R>Q		No	ClinGen ExAC gnomAD
CA6828541 rs11548262	48	R>W		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
CA6828537 rs771143682	53	P>R		No	ClinGen ExAC TOPMed gnomAD
rs749494544 CA6828536	57	V>L		No	ClinGen ExAC gnomAD
rs1304498175 CA386583647	58	R>C		No	ClinGen gnomAD
CA6828535 rs756587823	61	D>E		No	ClinGen ExAC TOPMed gnomAD
rs1461341163 CA386583595	63	R>G		No	ClinGen gnomAD
rs748662220 CA6828533	63	R>Q		No	ClinGen ExAC TOPMed gnomAD
rs773441188 CA6828483	66	E>D	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA gnomAD
rs1445525577 CA386582486	78	G>V		No	ClinGen TOPMed
rs368613719 CA6828480	81	R>Q		No	ClinGen ESP ExAC TOPMed gnomAD
CA386582384 rs1191247439	83	R>L		No	ClinGen gnomAD
CA386582344 rs1485838742	85	E>A		No	ClinGen gnomAD
rs766309580 CA244477275	87	P>S		No	ClinGen Ensembl
CA386582296 rs1256559379	88	R>G	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
CA6828478 rs749575527	90	Y>C		No	ClinGen ExAC TOPMed gnomAD
rs748728409 CA6828476	93	R>P		No	ClinGen ExAC TOPMed gnomAD
rs748728409 CA6828475	93	R>Q		No	ClinGen ExAC TOPMed gnomAD
rs778110680 CA244477252	93	R>W		No	ClinGen Ensembl
rs1565917169 CA386582220	94	G>S		No	ClinGen Ensembl
CA386582173 rs1339292774	96	W>*		No	ClinGen gnomAD
CA386582176 rs1339292774	96	W>C		No	ClinGen gnomAD
rs1276932808 CA386582150	98	R>C		No	ClinGen gnomAD
rs372846202 CA6828474	98	R>H		No	ClinGen ESP ExAC TOPMed gnomAD
CA6828473 rs755713912	99	G>A		No	ClinGen ExAC TOPMed gnomAD
CA244477231 rs755713912	99	G>D		No	ClinGen ExAC TOPMed gnomAD
rs781010036 CA6828471	102	N>S		No	ClinGen ExAC TOPMed gnomAD
CA6828470 rs754798032	104	P>T		No	ClinGen ExAC gnomAD
rs751502897 CA6828469	109	S>T		No	ClinGen ExAC gnomAD
rs1404129514 CA386581259	120	P>L		No	ClinGen TOPMed
rs1408867312 CA386581239	121	S>L		No	ClinGen gnomAD
rs199677891 CA244476194	125	Q>*		No	ClinGen 1000Genomes
CA6828446 rs762055178	137	V>I		No	ClinGen ExAC gnomAD
rs1338319321 CA386580978	140	A>V		No	ClinGen Ensembl
rs200633374 CA244476140	143	Q>R		No	ClinGen 1000Genomes
CA244476132 rs368340216	144	K>N		No	ClinGen ExAC gnomAD
CA244476135 rs1039523251	144	K>Q		No	ClinGen Ensembl
CA6828442 rs775678993	145	D>N		No	ClinGen ExAC TOPMed gnomAD
CA6828441 rs767909905	147	V>M		No	ClinGen ExAC gnomAD
rs760013988 CA6828440	149	M>I		No	ClinGen ExAC gnomAD
rs1262147988 CA386580841	150	V>A		No	ClinGen TOPMed
CA244476095 rs909022001	154	R>T		No	ClinGen Ensembl
rs1291650108 CA386580719	158	M>V		No	ClinGen gnomAD
rs752594381 CA244476090	159	E>D		No	ClinGen Ensembl
CA386580636 rs1158142117	163	R>H		No	ClinGen gnomAD
rs776216215 CA6828436	167	D>E		No	ClinGen ExAC gnomAD
TCGA novel	167	D>Y	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs201631930 CA6828434	171	R>C		No	ClinGen ExAC TOPMed gnomAD
CA6828433 rs374865867	171	R>H		No	ClinGen ESP ExAC TOPMed gnomAD
rs1334997585 CA386579858	179	Y>H		No	ClinGen TOPMed
CA244474588 rs749288623	181	R>*		No	ClinGen ExAC gnomAD
rs777693373 CA6828405	181	R>Q		No	ClinGen ExAC gnomAD
CA386579796 rs1170525466	184	P>S		No	ClinGen gnomAD
CA244474577 rs148192217	190	Y>C		No	ClinGen ESP TOPMed
CA6828402 rs201844994	192	Y>*		No	ClinGen ExAC gnomAD
CA386579714 rs1423438628	192	Y>C		No	ClinGen gnomAD
rs752857364 CA6828403	192	Y>H		No	ClinGen ExAC gnomAD
rs1592989913 CA386579692	194	R>P		No	ClinGen Ensembl
CA6828401 rs755203606	195	S>A		No	ClinGen ExAC
rs1179019404 CA386579674	196	R>Q		No	ClinGen gnomAD
rs1592989898 CA386579662	197	S>A		No	ClinGen Ensembl
CA386579642 rs1592989889	199	S>A		No	ClinGen Ensembl
rs1459351343 CA386579621	201	G>S		No	ClinGen TOPMed
CA6828399 rs766758485	202	R>C		No	ClinGen ExAC gnomAD
CA6828398 rs139360328 COSM430510	202	R>H	Variant assessed as Somatic; 0.0 impact. breast [NCI-TCGA, Cosmic]	No	ClinGen cosmic curated 1000Genomes ESP ExAC NCI-TCGA TOPMed gnomAD
CA386579564 rs1273558571	206	Y>N		No	ClinGen gnomAD
rs750984394 CA6828397	208	S>N		No	ClinGen ExAC gnomAD
CA386579524 rs1256013029	209	R>G		No	ClinGen TOPMed
CA386579522 rs1338335039	209	R>K		No	ClinGen gnomAD
CA386579519 rs1338335039	209	R>M		No	ClinGen gnomAD
rs763511362 CA6828396	209	R>S		No	ClinGen ExAC TOPMed gnomAD
CA6828394 rs775156072	210	G>D		No	ClinGen ExAC gnomAD
CA6828395 rs760167949	210	G>S		No	ClinGen ExAC TOPMed gnomAD
rs759295143 CA6828392	212	P>S		No	ClinGen ExAC gnomAD
rs774258544 CA6828391	213	H>Q		No	ClinGen ExAC gnomAD
CA244474475 rs940710190	213	H>R		No	ClinGen TOPMed gnomAD
CA6828389 rs370436477	215	F>Y		No	ClinGen ESP ExAC TOPMed gnomAD
CA244474462 rs776930825	216	S>C		No	ClinGen gnomAD
CA244474451 rs776930825	216	S>F		No	ClinGen gnomAD
CA386579427 rs1419929391	218	F>V		No	ClinGen gnomAD
CA6828387 rs769622746	220	P>L		No	ClinGen ExAC gnomAD
rs1253624010 CA386579385	221	Y>*		No	ClinGen TOPMed gnomAD
rs748166545 CA6828386	222	Y>W		No	ClinGen ExAC gnomAD

No associated diseases with Q13242

4 regional properties for Q13242

Type	Name	Position	InterPro Accession
domain	RNA recognition motif domain	14 - 89	IPR000504-1
domain	RNA recognition motif domain	111 - 187	IPR000504-2
domain	SRSF9, RNA recognition motif 1	15 - 86	IPR034503
domain	SRSF9, RNA recognition motif 2	104 - 186	IPR034995

Functions

		Description
EC Number
Subcellular Localization	Nucleus	Cellular stresses such as heat shock may induce localization to discrete nuclear bodies termed SAM68 nuclear bodies (SNBs), HAP bodies, or stress bodies Numerous splicing factors including SRSF1/SFRS1/SF2, SRSF7/SFRS7, SAFB and KHDRBS1/SAM68 accumulate at these structures, which may participate in the post-transcriptional regulation of mRNAs in stressed cells
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category	No pathway information available

3 GO annotations of cellular component

Name	Definition
nuclear speck	A discrete extra-nucleolar subnuclear domain, 20-50 in number, in which splicing factors are seen to be localized by immunofluorescence microscopy.
nucleolus	A small, dense body one or more of which are present in the nucleus of eukaryotic cells. It is rich in RNA and protein, is not bounded by a limiting membrane, and is not seen during mitosis. Its prime function is the transcription of the nucleolar DNA into 45S ribosomal-precursor RNA, the processing of this RNA into 5.8S, 18S, and 28S components of ribosomal RNA, and the association of these components with 5S RNA and proteins synthesized outside the nucleolus. This association results in the formation of ribonucleoprotein precursors; these pass into the cytoplasm and mature into the 40S and 60S subunits of the ribosome.
nucleoplasm	That part of the nuclear content other than the chromosomes or the nucleolus.

2 GO annotations of molecular function

Name	Definition
protein domain specific binding	Binding to a specific domain of a protein.
RNA binding	Binding to an RNA molecule or a portion thereof.

7 GO annotations of biological process

Name	Definition
alternative mRNA splicing, via spliceosome	The process of generating multiple mRNA molecules from a given set of exons by differential use of exons from the primary transcript(s) to form multiple mature mRNAs that vary in their exon composition.
mRNA processing	Any process involved in the conversion of a primary mRNA transcript into one or more mature mRNA(s) prior to translation into polypeptide.
mRNA splice site selection	Selection of a splice site by components of the assembling spliceosome.
mRNA splicing, via spliceosome	The joining together of exons from one or more primary transcripts of messenger RNA (mRNA) and the excision of intron sequences, via a spliceosomal mechanism, so that mRNA consisting only of the joined exons is produced.
negative regulation of mRNA splicing, via spliceosome	Any process that stops, prevents or reduces the rate or extent of mRNA splicing via a spliceosomal mechanism.
response to alkaloid	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an alkaloid stimulus. Alkaloids are a large group of nitrogenous substances found in naturally in plants, many of which have extracts that are pharmacologically active.
response to toxic substance	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a toxic stimulus.

2 homologous proteins in AiPD

UniProt AC	Gene Name	Protein Name	Species	Evidence Code
Q9D0B0	Srsf9	Serine/arginine-rich splicing factor 9	Mus musculus (Mouse)	PR
Q5PPI1	Srsf9	Serine/arginine-rich splicing factor 9	Rattus norvegicus (Rat)	PR

10	20	30	40	50	60
MSGWADERGG	EGDGRIYVGN	LPTDVREKDL	EDLFYKYGRI	REIELKNRHG	LVPFAFVRFE
70	80	90	100	110	120
DPRDAEDAIY	GRNGYDYGQC	RLRVEFPRTY	GGRGGWPRGG	RNGPPTRRSD	FRVLVSGLPP
130	140	150	160	170	180
SGSWQDLKDH	MREAGDVCYA	DVQKDGVGMV	EYLRKEDMEY	ALRKLDDTKF	RSHEGETSYI
190	200	210	220
RVYPERSTSY	GYSRSRSGSR	GRDSPYQSRG	SPHYFSPFRP	Y